Karla B Peña1, Francesc Riu1, Josep Gumà2, Carmen Guilarte1, Berta Pique1, Anna Hernandez1, Alba Àvila3, Sandra Parra3, Antoni Castro3, Conxita Rovira4, Pitter Cueto4, Immaculada Vallverdu4, David Parada1. 1. Pathology Molecular Unit, Department of Pathology, Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària Pere Virgili, Facultat de Medicina, Universitat Rovira i Virgili, 43204 Reus, Spain. 2. Department of Oncology, Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària Pere Virgili, Facultat de Medicina, Universitat Rovira i Virgili, 43204 Reus, Spain. 3. Department of Internal Medicine, Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària Pere Virgili, Facultat de Medicina, Universitat Rovira i Virgili, 43204 Reus, Spain. 4. Department of Intensive Care Medicine, Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària Pere Virgili, Facultat de Medicina, Universitat Rovira i Virgili, 43204 Reus, Spain.
Abstract
The pandemic caused by the SARS-CoV-2 infection affects many aspects of public health knowledge, science, and practice around the world. Several studies have shown that SARS-CoV-2 RNA in plasma seems to be associated with a worse prognosis of COVID-19. In the present study, we investigated plasma and buffy RNA in patients with COVID-19 to determine its prognostic value. A prospective study was carried out in patients hospitalized for COVID-19, in which RNA was analyzed in plasma and the buffy coat. Morphological and immunohistochemical studies were used to detect the presence of SARS-CoV-2 in the buffy coat. In COVID-19 patients, the obtained RNA concentration in plasma was 448.3 ± 31.30 ng/mL. Of all the patients with positive plasma tests for SARS-CoV-2, 46.15% died from COVID-19. In four cases, tests revealed that SARS-CoV-2 was present in the buffy coat. Abnormal morphology of monocytes, lymphocytes and neutrophils was found. An immunohistochemical study showed positivity in mononuclear cells and platelets. Our results suggest that SARS-CoV-2 is present in the plasma. This facilitates viral dissemination and migration to specific organs, where SARS-CoV-2 infects target cells by binding to their receptors. In our study, the presence of plasma SARS-CoV-2 RNA was correlated with worse prognoses.
The pandemic caused by the n class="Disease">SARS-CoV-2 infection affects many aspects of public health knowledge, science, and practice around the world. Several studies have shown that SARS-CoV-2 RNA in plasma seems to be associated with a worse prognosis of COVID-19. In the present study, we investigated plasma and buffy RNA in patients with COVID-19 to determine its prognostic value. A prospective study was carried out in patients hospitalized for COVID-19, in which RNA was analyzed in plasma and the buffy coat. Morphological and immunohistochemical studies were used to detect the presence of SARS-CoV-2 in the buffy coat. In COVID-19patients, the obtained RNA concentration in plasma was 448.3 ± 31.30 ng/mL. Of all the patients with positive plasma tests for SARS-CoV-2, 46.15% died fromCOVID-19. In four cases, tests revealed that SARS-CoV-2 was present in the buffy coat. Abnormal morphology of monocytes, lymphocytes and neutrophils was found. An immunohistochemical study showed positivity in mononuclear cells and platelets. Our results suggest that SARS-CoV-2 is present in the plasma. This facilitates viral dissemination and migration to specific organs, where SARS-CoV-2 infects target cells by binding to their receptors. In our study, the presence of plasma SARS-CoV-2 RNA was correlated with worse prognoses.
Entities:
Keywords:
RNA; SARS-CoV-2; blood; buffy coat; immunohistochemical; morphology; plasma
Authors: Mamadi Yilla; Brian H Harcourt; Carole J Hickman; Marcia McGrew; Azaibi Tamin; Cynthia S Goldsmith; William J Bellini; Larry J Anderson Journal: Virus Res Date: 2005-01 Impact factor: 3.303
Authors: Olga Pozdnyakova; Nathan T Connell; Elisabeth M Battinelli; Jean M Connors; Geoffrey Fell; Annette S Kim Journal: Am J Clin Pathol Date: 2020-12-03 Impact factor: 2.493
Authors: Richard Wargodsky; Philip Dela Cruz; John LaFleur; David Yamane; Justin Sungmin Kim; Ivy Benjenk; Eric Heinz; Obinna Ome Irondi; Katherine Farrar; Ian Toma; Tristan Jordan; Jennifer Goldman; Timothy A McCaffrey Journal: PLoS One Date: 2022-01-26 Impact factor: 3.240